KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Convertible Debt (2016 - 2025)

Ionis Pharmaceuticals has reported Convertible Debt over the past 17 years, most recently at $751.5 million for Q4 2025.

  • Quarterly results put Convertible Debt at $751.5 million for Q4 2025, up 33.0% from a year ago — trailing twelve months through Dec 2025 was $751.5 million (up 33.0% YoY), and the annual figure for FY2025 was $751.5 million, up 33.0%.
  • Convertible Debt for Q4 2025 was $751.5 million at Ionis Pharmaceuticals, up from $567.1 million in the prior quarter.
  • Over the last five years, Convertible Debt for IONS hit a ceiling of $751.5 million in Q4 2025 and a floor of $44.3 million in Q3 2023.
  • Median Convertible Debt over the past 5 years was $565.4 million (2024), compared with a mean of $559.5 million.
  • Biggest five-year swings in Convertible Debt: plummeted 91.86% in 2023 and later surged 1174.27% in 2024.
  • Ionis Pharmaceuticals' Convertible Debt stood at $542.3 million in 2021, then rose by 0.3% to $544.0 million in 2022, then increased by 3.37% to $562.3 million in 2023, then rose by 0.49% to $565.0 million in 2024, then skyrocketed by 33.0% to $751.5 million in 2025.
  • The last three reported values for Convertible Debt were $751.5 million (Q4 2025), $567.1 million (Q3 2025), and $565.7 million (Q1 2025) per Business Quant data.